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The combination of thrombophilia and pregnancy increases the risk of thrombosis and the potential for adverse outcomes during
pregnancy. The most signiﬁcant common inherited risk factor for thrombophilia is activated protein C resistance (APCR), a poor
anticoagulant response of APC in haemostasis, which is mainly caused by an inherited single-nucleotide polymorphism (SNP),
factor V G1691A (FV Leiden) (FVL), referred as inherited APCR. Changes in the levels of coagulation factors: FV, FVIII, and
FIX, and anticoagulant factors: protein S (PS) and protein C (PC) can alter APC function causing acquired APCR. Prothrombin
G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T are prothrombotic SNPs which in association with APCR
can also increase the risk of thrombosis amongst Caucasians. In this study, a correlation between an acquired APCR phenotype
and increased levels of factors V, VIII, and IX was demonstrated. Thrombophilic mutations amongst our acquired APCR pregnant
women cohort are relatively common but do not appear to exert a severe undue adverse eﬀect on pregnancy.
1.Introduction
Pregnancyincreasestheriskofthrombosis.APCRphenotype
has been associated with venous thromboembolism (VTE),
the primary cause of maternal death in developed countries
[1–3].
In normal conditions, APC inactivates the coagulant
protein active FV(a) by cleaving in an ordered sequence
speciﬁc sites of FV(a). The ﬁrst cleavage site is Arginine
(Arg) 506, and the second is (Arg) 306 followed by (Arg)
679 [4]. Mutations in the FV gene have been related to
APCR. FVL is reported in about 90% of patients with
APCR in the general population [5–7]. Other SNPs in the
factor V gene which may contribute to inherited APCR
either independently or found in association with the FVL
mutation include Cambridge Arg306, Hong Kong, Arg306, the
Arg679, and the haplotype (H) R2 and R3 polymorphisms.
However, reports on the contribution of these mutations to
the APCR phenotype are conﬂicting [7–10].
ThepathophysiologyunderlyingAPCRnotcausedbythe
FVL mutation is still not completely understood. In diﬀerent
studies, it has been suggested that acquired factors might be
the cause of APCR in the absence of FV Leiden [11, 12]. A
number of coagulation factors can aﬀect the activated partial
thromboplastin time (aPTT). Previous literature suggested a
possible positive correlation between levels of factors V, VIII
and IX and acquired APCR [13] .P r o t e i nSa n dp r o t e i nC ,
levels can (or may) aﬀect acquired APCR, but their inﬂuence
on the resistance seems to be still within the range of normal
levels [14].2 Journal of Pregnancy
Other known SNPs associated with thrombophilia and
adverse outcomes during pregnancy are prothrombin
G20210A and MTHFR C677T [15–17].
Prothrombin G20210A is associated with an increase in
thelevelofprothrombinprotein(FII)inplasmaandaresult-
ing 3-fold increase in thrombotic events. The prothrombin
G20210A mutation seems to increase the risk of thrombosis
in pregnant women by approximately tenfold [18]w i t h
the risk of developing obstetric complications increased by
fourfold [16].
The MTHFR C677T has been associated with obstetric
complications and with birth defects [19, 20].
In a previous study in this laboratory, we identiﬁed
known and novel SNPs in a small number of subjects with
APCR determined using the modiﬁed Coatest test which did
not have the FVL mutation [21].
The main objectives of this study were to (1) determine
and compare the levels of factors V, VIII, and IX in
the acquired APCR, inherited APCR, and APCR-negative
groups, (2) compare the frequency of adverse outcomes
in the APCR-positive (acquired and inherited) and APCR-
negative groups, and (3) determine the frequency of adverse
pregnancy outcomes, associated with thrombophilic muta-
tions other than FVL mutation in our study cohort (n =
907).Theadversepregnancyoutcomesobservedinthisstudy
included (previous) recurrent early pregnancy loss (REPL),
preeclampsia (PET), and intrauterine growth restriction
(IUGR). Pregnancy induced hypertension (PIH), (IUFD)
intrauterine fetal dead, and low birth weight (LBW).
2.MaterialsandMethods
2.1. Subjects. Ethical approval for the study was obtained
from the Research Ethics Committee, and written consent
for samples to be collected was obtained from the 907
pregnant women included in this study who attended for
routine outpatient gestational screening at the antenatal
clinic at University College Hospital, Galway, (UCHG).
Table 1 details the demographics of the study subjects.
Blood samples (Lithium Heparin and EDTA) were col-
lected from subjects between the 16th to 24th weeks of
gestation. In this second trimester of pregnancy, little or
almost no variation on the coagulation factors has been
shown which is appropriate for the assessment of APC status
[22]. Testing of APC status before or from 8 to 12 weeks
after pregnancy or more frequently during pregnancy would
have determined a more accurate stable APC ratio; this is
a limitation of the current study. The laboratory analysis of
poor anticoagulant response to APC is based on an activated
partial thromboplastin time (aPTT) assay. A reduced ratio
reﬂectsthe reduced rate of inactivation. The cutoﬀ ratio used
to determine positive APCR for this study was a value of less
than or equal to 2.1 seconds (s). This value was determined
by the haematology department and it is in clinical use at
UCHG. The cut-oﬀ ratio used to determine APCR can vary
in sensitivity and speciﬁcity depending on the methodology,
equipment, and technology used in diﬀerent laboratories.
2.2. APC Status by Classic Coatest Test in Order to Identify
Acquired APCR Samples. Blood samples were centrifuged at
4,000rpm for 5min, and aliquots of platelet-poor plasma
were frozen at −80◦C until the assay took place. Plasma was
incubated with an equal volume of aPTT reagent for 5 min
at 37◦C. Clotting was initiated by the addition of CaCl2,a n d
clotting times were expressed as a ratio of clotting time in the
presence of APC divided by the clotting time in the absence
of APC.
2.3. APC Status by Modiﬁed Coatest Test in Order to Identify
Inherited APCR Samples. Blood samples were ﬁrst diluted 1
in 5 with factor V-deﬁcient plasma that contains a heparin
neutralizer, and then it was assayed as described for the
APCR classic Coatest test. The addition of the factor V-
deﬁcientplasmacorrectsfordeﬁcienciesofothercoagulation
proteins, neutralises therapeutic concentrations of heparin,
andeliminatestheeﬀectofsomelupusinhibitors[23].APCR
in the presence of factor V-depleted plasma was assessed
using the Coatest APCR-kit and factor V-depleted plasma
(Chromogenix) [24].
2.4. DNA Extraction. DNA was extracted from blood sam-
plesforallAPCRsubjects(n=140)andcontrolsamples(neg-
ative APCR n = 31) using a modiﬁcation of the CF(12)m-
PCR protocol by Ortho-Clinical Diagnostics, Amersham,
UK. Spectrophotometric analysis of absorbance at 260nm
was performed in a Heλios α spectrophotometer (Unicam
Ltd., England) for each DNA sample, and the average yield
for DNA was determined to be 30ng/μL.
2.5. Mutation Screening. PCR-restriction enzyme analysis
(PCR-REA) was applied to identify G20210A in the FII gene,
C677T in the MTHFR gene, and FVL, FV Cambridge, FV
Hong Kong mutations, and Haplotype (H) R2, allele in
the FV gene using modiﬁcations of previously published
methods [6, 25–29]. DNA probe hybridisation analysis
and/or DNA sequencing was applied for Arg679 detection
as described [21]. One hundred and forty APCR-positive
subjects and 31 APCR-negative subjects were tested for
all mutations. Our group of control subjects tested for
thrombophilic mutations, n = 31, was chosen randomly out
of the 767 negative APCR subjects identiﬁed as normal with
the APCR classic Coatest test. A mean of 2.59 and standard
deviation of 0.2804 were identiﬁed for this negative APCR
group of n = 767 subjects. Conversely, a mean of 1.745 and
standard deviation of 0.1104 were identiﬁed for the positive
APCR (inherited plus acquired) n = 140. The minimum
value identiﬁed for negative APCR was 2.160 whereas for
positive APCR was 1.490. The maximum negative APCR
value identiﬁed was 3.030, whereas for positive APCR it was
2.060seconds.Thrombophilicmutationsareinterferingwith
thecoagulationequilibriumvaryingtheaPTTtimerelatedto
APC ratio range.
All mutations were screened in duplicate and positive
controls consisting of DNA from heterozygous and homozy-
gous individuals for FVL and MTHFR-C677T mutations,Journal of Pregnancy 3
Table 1: Demographics of study cohort (n = 907) pregnant woment attending for antenatal care at UCH, Galway.
Positive APCR Negative APCR
Distribution of parity by total population
Parity Freq % Freq %
Primigravida 59 42.2 301 40.3
Multigravida 81 57.8 226 59.7
Data missing 0 0 15 1.9
Total 140 100 767 100
Distribution of maternal age by total population
Maternal age Freq % Freq %
<19 12 8.6 38 5.1
20–29 29 20.7 143 19
30–39 87 62.1 473 62.9
40 < 45 12 8.6 98 13
Data missing 0 0 15 0
Total 140 100 767 100
range 15–42 16–45
mean 28 29
Distribution of mode of delivery by total population
Mode of delivery Freq % Freq %
Spontaneous vaginal delivery 82 58.6 456 60.6
Assisted vaginal 27 19.3 121 16.1
Cesarean Section 29 20.7 158 21
Data missing 2 1.4 32 2.3
Total 140 100 767 100
Distribution of mode of delivery by total population
Mode of delivery Freq % Freq %
SVD 82 58.6 456 60.6
AV 27 19.3 121 16.1
CS 29 20.7 158 21
Data missing 2 1.4 32 2.3
Total 140 100 767 100
SVD: Spontaneous vaginal delivery; AV: Assisted vaginal; CS: Cesarean section.
and heterozygous individuals for other mutations inves-
tigated were included where it was available. A negative
control, consisting of water in place of DNA template, was
includedineachPCRrun.PCRampliﬁcationwasperformed
on the GeneAmp PCR System 9600 (Perkin Elmer, USA).
2.6. DNA Sequencing Verifying Mutations Identiﬁed. DNA
sequencing on 50% of the PCR products from subjects
screened for the Arg679 mutation was performed to verify
the normal genotype obtained by Southern blot-DNA probe
hybridisation analysis for these subjects. The 400bp PCR
products from Exon 13 containing the Arg679 site of the
FV gene were puriﬁed using the QIAprep Spin Miniprep
Kit (Qiagen Ltd, UK) according to the manufacturer’s
instructions and sent for DNA sequencing to an external
sequence service provider (MWG Biotech, Germany). One
sample positive for the Cambridge mutation by PCR/REA
analysis was also puriﬁed using the QIAprep Spin Miniprep
Kit (Qiagen Ltd, UK) and sent for sequencing to conﬁrm the
Arg306 mutation.
2.7. Levels of Factors V, VIII, and IX. Levels were determined
for the APCR-positive and APCR-negative groups using
a one-stage APTT assay on an MDA 180 coagulometer
(Organon Teknika, Cambridge, UK), using factors V, VIII
and IX deﬁcient plasma’s (Diagnostica Stago). The APCR
negative group comprised of 50 women selected at random
from diﬀerent batch runs of Coatest tests providing the basis
for the control group in comparing data between diﬀerent
variables.
Results for factors V, VIII, and IX levels were expressed
as percentage (%) levels, and the reference ranges used
[30] are currently in clinical use at the Haematology
Laboratory, UCHG. Each run was controlled by the use of
a normal (MDA verify 1, Biomerieux) and abnormal control
(coagulation control A, Technoclone GmbH).
2.8. Statistical Analysis of Pregnancy Adverse Outcomes in
the Group Observed in the 907 Women Included in the
Study. Data was collected from the Maternity Department
at UCHG. The number and type of pregnancy outcomes4 Journal of Pregnancy
Table 2: Comparison of factor V, VII and IX in positive APCR acquired and inherited and negative APCR groups.
Positive APCR Negative APCR
Correlation between levels of the coagulation factor V and APCR
Factor V levels Acquired APCR Inherited APCR
Number of values 85 22 50
Minimum value 89 110 88
Maximum value 171 180 149
Mean 131.5 131.7 114.6
Coeﬃcient of variation 13.35% 12.34% 13.49%
Correlation between levels of the coagulation factor VIII and APCR
Factor VIII levels Acquired APCR Inherited APCR
Maximum value 177 172 144
Minimum value 73 90 91
Mean 128.7 120.2 111.9
Coeﬃcient of variation 16.79% 18.10% 12.14%
Correlation between levels of the coagulation factor IX and APCR
Factor IX levels Acquired APCR Inherited APCR
Number of values 85 22 50
Minimum value 90 85 89
Maximum value 167 169 125
Mean 114.8 114.2 106.9
Coeﬃcient of variation 11.93% 16.25% 8.53%
studied were analysed using SPSS version 17.0 software. The
Pearson Chi Square test was used to compare the APCR-
positive group and the negative APCR group to analyze the
thrombophilic mutations and the range of adverse outcomes
associated with each group. The Pearson Chi-Square test was
used to compare the number and type of adverse pregnancy
outcomesintheinheritedversusacquiredAPCRgroup.SPSS
was used to analyse the levels of coagulation factors V, VIII,
and IX using Kruskal-Wallis statistical testing.
2.9. Criteria for Adverse Outcomes Diagnosis. PET-BP (Blood
pressure) ≥140/90mmHg,+1proteinuriaandoedema.PIH-
BP ≥140/90 with no proteinuria in accordance with the
Oﬃcial Journal of the International Society for the Study of
Hypertension in Pregnancy. IUGR is deﬁned as fetal growth
of less than 5th percentile for gestational age [25]. LBW is
deﬁned as a weight of less than 2500g (up to and including
2499g), irrespective of gestational age.
3. Results
We identiﬁed 15.4% (n=140) of the study cohort (n = 907)
as APCR positive with acquired and/or inherited Coatest
tests. Factors V, VIII, and IX levels showed a positive
correlation with an acquired APCR phenotype. The levels
for each factor in the APCR positive (inherited) and APCR-
positive (acquired) and APCR-negative groups are shown in
Table 2 and Figure 1. Levels of factors V, VIII, and IX in the
acquired APCR group were signiﬁcantly higher compared
to the normal control group. The means were factor V
131.5IU/dL versus 114.6IU/dL for the control group, factor
VIII 128.7IU/dL versus 111.9IU/dL in the control group
and factor IX 114.8IU/dL versus 106.9IU/dL in the control
group.
Ninety-two subjects (66%) of the positive APCR group
had common thrombophilic mutations, 32% of whom had
the FVL mutation. A total of n = 116 mutations were
identiﬁed in this group, 68 subjects had one mutation, 23
hadtwomutations,1subjecthadthreemutations,andforty-
eight subjects did not have any of the known mutations
screened for.
Within the acquired (without FVL) positive APCR (n =
105), 70 mutations were distributed among 61 subjects who
had one or more of these mutations. Within the negative
APCR group (n = 31), 18 subjects had one mutation. The
distribution of thrombophilic mutations is summarised in
Table 3.
Frequencies of adverse outcomes in positive APCR and
negativeAPCRgroupswereverysimilarat35.7%and34.2%,
respectively (Table 4). The comparison of adverse pregnancy
outcomes and thrombophilic mutations is summarised in
Table 5. PIH showed statistical signiﬁcant (P< 0.05) asso-
ciation with Cambridge and prothrombin G20210A. LBW
showed statistical signiﬁcant (P< 0.05) association with
HR2 and MTHFR.
4. Discussion
The frequency of APCR has been reported as approximately
5% in the general Caucasian population [31, 32]. This varies
from 1% to 15% in diﬀerent countries with a frequency
of 3% reported in Italy and Spain and a frequency ofJournal of Pregnancy 5
Table 3: Distribution of the thrombophilic mutations identiﬁed in our study cohort.
APC Mutations
identiﬁed/subjects tested
Frequency from the subset of
subjects tested in each group
(∗1) (∗2), (∗3).
Frequency from the
total cohort n = 907
Thrombophilic mutations
identiﬁed
(∗1) n = 140 Positive APCR
(inherited and acquired)
67/140 47.8% 7.3% MTHFR-C677T
(54ht13hom)
3 /140 2.1% 0.3% ht prothrombin G20210A
16/140 11.4% 1.7% ht (H) R2
29/140 20.7% 3.1% ht FV Leiden
1/140 0.7% 0.1% ht Cambridge
48/140 31.4% 3.9% no mutation
(∗2) n = 105 Positive APCR (acquired)
51/105 48.5% 5.6% MTHFR -C677T
(38ht13hom)
3/105 2.8% 0.3% ht Prothrombin G20210A
16/105 15.2% 1.7% ht(H) R2
44/105 41.9% 4.8% no mutations
(∗3) n = 31 Negative APCR
5/31 16.1% 0.6% ht (H) R2
13/31 41.9% 1.7% MTHFR-C677T
13/31 41.9% 1.7% No mutation
(∗1) n = 140 are subjects with total APCR (acquired +modiﬁed).
(∗2) n = 105 are subjects with acquired APCR, without inherited FVL.
(∗3) n = 31 are negative APCR subjects tested out of 767.
n:N u m b e ro fs u b j e c t s ;h t :H e t e r o z y g o t e s ;h o m :H o m o z y g o t e s ;H :H a p l o t y p e .
Subjects identiﬁed with more than one mutation simultaneously:
in the total APCR group, (inherited plus acquired) They had 13 subjects with MTHFR+FVL; 1subject with MTHFR + FVL + Cambridge; 7 subjects with
MTHFR + HR2; 1 subject with prothrombin G20210A + HR2; and 1 subject with prothrombin G20210A + MTHFR; in the acquired APCR group, They had
7 subjects with MTHFR+HR2; 1 subject with prothrombin G20210A + HR2; 1 subject with prothrombin G20210A + MTHFR.
Table 4: Frequency of adverse outcomes identiﬁed in positive APCR (acquired plus inherited) versus negative APCR. P value from Pearson
Chi-Square test applied to positive APCR (acquired plus inherited) versus negative APCR.
Total outcomes
frequency EPL PET PIH IUGR IUFD LBW
Positive N = 140 N = 50 N = 38 N = 3 N = 12 N = 1 N = 0 N = 37
APCR Freq.% 35.7% 27.1 % 2.2% 8.6% 0.7% 0% 26.8%
Negative N = 767 N = 262 N = 196 N = 39 N = 37 N = 20 N = 3 N = 256
APCR Freq.% 34.2% 25.7% 5.2% 4.9% 2.6% 0.4% 34.5%
Pearson
Chi-Square P value 0.722 0.712 0.125 0.077 0.168 0.456 0.080
Table 5: Results from Pearson Chi-Square test. P values for the association between each adverse pregnancy outcome identiﬁed in this study
and thrombophilic mutations indentiﬁed in our total study cohort n = 907.
P values Presence of outcomes EPL PET PIH IUGR IUFD LBW
FVL 0.237 0.832 0.748 0.004 0.396 0.751 0.289
Cambridge 0.469 0.554 0.822 0.000 0.877 0.954 0.480
HR2 0.951 0.654 0.194 0.466 N/A N/A 0.016
Prothrombin 0.426 0.133 0.928 0.008 0.413 0.883 0.907
MTHFR 0.859 0.203 0.428 0.584 N/A N/A 0.048
NA: no statistics are computed because there is no IUGR in the MTHFR and HR2 groups.6 Journal of Pregnancy
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Figure 1: (a) Graph comparing FV levels in diﬀering groups within the study, (b) graph comparing FVIII levels in diﬀering groups within
the study, and (c) graph comparing F IX levels in diﬀering groups within the study.
15% reported in Northern Sweden [33]. APCR in the
general population and during pregnancy is reported to be
most frequently caused by FVL mutation [34–36], inherited
APCR.
Several reports have shown, however, that between 5 and
10% of APCR in Caucasians does not involve the FVL,
and the cause of positive APCR in these cases is not
known [34, 37–40]. In our study cohort (n = 907), the
frequency of acquired APCR, determined by the classic
Coatest test method, of 11.5%, was substantially higher than
the frequency of inherited APCR identiﬁed by modiﬁed
Coatest tests, 3.9%. De Visser et al. demonstrated that anJournal of Pregnancy 7
altered APCR in the absence of FVL confers a 2.5-fold
increased risk for venous thrombosis [41].
In this study, a signiﬁcant statistical correlation of the
acquired APCR phenotype with Factors V, VIII, and IX
levels was demonstrated. Further study would be required to
determine the interaction of coagulation factors to further
characterize this acquired APCR phenotype in early preg-
nancy. Acquired APCR can be the result of a complex series
of reactions giving a defective APC-mediated degradation
of these coagulation factors. In turn, an increase of these
coagulation factors in early pregnancy stages could cause an
imbalance in the coagulation cascade and lead to vascular
and endothelial damage during implantation and placenta-
tion. This has the potential to cause placental infarcts and
high levels of ﬁbrin deposition, which has been previously
associated with APCR [42]. Spontaneous abortion may take
place in response to an increased coagulation imbalance, and
ifthereareotherthromboticfactorsincludingthrombophilic
mutations interacting simultaneously when the subject is
beyond the 20th week of pregnancy, the damage could
develop into PET or PIH.
Mutations in the FV gene excluding FVL, particularly
at the other cleavage sites of FV, Arg306,a n dA r g 679,h a v e
the potential to contribute to the APCR phenotype [6, 43].
Haplotype (H) R2 has also been associated with mild APCR
when found in combination with the FVL [7, 10, 44, 45].
There have been a number of other mutations identiﬁed in
the FV gen; however, a larger pregnant population would
needtobestudiedtodetermineifthesemutationscontribute
signiﬁcantly to APCR in the Caucasian populations [21, 46–
48]. Thrombophilia during pregnancy has been linked with
mutations other than those located in the FV gene including
prothrombin G20210A and MTHFR-C677T [17, 49, 50]. In
this study, we identiﬁed thrombophilic mutations in 66%
of our positive APCR (acquired plus inherited) group (n =
140). One of those subjects had 2 mutations in the FV gene,
FVLand FVCambridge-G1091C, attwo cleavagessites ofFV
forAPC[21].Thissubjectwasalsofoundinthisstudytobea
carrier of MTHFR-C677T mutation. Previous studies estab-
lished that the presence of more than one prothrombotic
polymorphism is associated with a substantial risk of VTE
with a high risk of adverse pregnancy outcomes [51, 52]. In
addition, more recently MTHFR-C677T mutation has been
implicatedinpre-eclampsia.ThehighfrequencyofMTHFR-
C677T in the negative APCR and positive APCR groups may
underlie populations-speciﬁc diﬀerences [53]. Discrepancies
in the adverse pregnancy outcomes associated with MTHFR-
C677Tmaybeexplainedbythespeciﬁcfrequencydiﬀerences
among populations [54, 55].
We also identiﬁed prothrombin G20210A in 3 subjects
in the acquired APCR group without the presence of FVL
mutation, with the (H) HR2 haplotype and MTHFR-C677T
identiﬁed in both positive APCR (acquired plus inherited)
and negative APCR groups.
The negative APCR samples (n = 31) tested for throm-
bophilic mutations in this study to represent the normal
cohort are a small sample number, and this may be a ﬂaw
in our study resulting in nonsigniﬁcant diﬀerences. Testing
a larger number of negative APCR would have given more
conﬁdent results. This can be something to be investigated in
af u t u r es t u d y .
While some previous studies have shown an association
of positive APCR with PET, IUGR, and IUFD [55] in this
study there was no signiﬁcant diﬀerence in the frequency
of adverse outcomes between positive APCR and negative
APCR groups. This seems to be consistent with other
previous studies [56]. Nonetheless, the overall frequency
adverse pregnancy outcomes in the positive APCR makes
this study group “a high-risk group.” Environmental factors
such as smoking and body mass index (BMI) that could have
inﬂuenced the rate of acquired APCR and the frequency of
adverse outcomes identiﬁed, were not included. This is a
limitation of the study.
In our total study group, thrombophilic mutations
including FVL Cambridge and Prothrombin G20210A seem
to be related to PIH, whereas MTHFR-C677T and HR2
haplotype appeared to be associated with LBW. Although
positive APCR by itself does not seem to be the cause of
severe adverse outcomes during pregnancy, inherited APCR
can nevertheless have an eﬀect on hypertension when it is
present in combination with other known and unknown
thrombophilic risk factors acting simultaneously during
pregnancy.
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